Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

Over the past decade, targeted therapy for oncogene-driven NSCLC and immune checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved the survival and quality of life for patients with unresectable NSCLC. Increasingly, these biomarker-guided systemic therapies given be...

Descripción completa

Detalles Bibliográficos
Autores principales: Godoy, Luis A., Chen, Joy, Ma, Weijie, Lally, Jag, Toomey, Kyra A., Rajappa, Prabhu, Sheridan, Roya, Mahajan, Shirish, Stollenwerk, Nicholas, Phan, Chinh T., Cheng, Danny, Knebel, Robert J., Li, Tianhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847175/
https://www.ncbi.nlm.nih.gov/pubmed/36650586
http://dx.doi.org/10.1186/s40364-022-00444-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847175/
https://www.ncbi.nlm.nih.gov/pubmed/36650586
http://dx.doi.org/10.1186/s40364-022-00444-7

Ejemplares similares